Canaccord cuts Intercept to hold, calls Alfasigma deal “best possible outcome” (ICPT)


word m and a made with wood building blocks, stock image

Maksim Labkouski

Intercept Pharmaceuticals (NASDAQ:ICPT) has been downgraded to hold by Canaccord Genuity in the wake of news that the biotech group has agreed to be acquired by Alfasigma for $19 per share in cash.

Canaccord said in a note that it

Source link

Leave A Reply

Your email address will not be published.